Women's Health Drugs Flashcards Preview

NCLEX > Women's Health Drugs > Flashcards

Flashcards in Women's Health Drugs Deck (28):
0

Alendronate (Fosamax)
(Functional Classification)

Bone-resorption inhibitor

1

Alendronate (Fosamax)
(Chemical Classification)

Bisphosphate

2

Alendronate (Fosamax)
(Mechanism of Action)

Decreases rate of bone resorption and may directly block dissolution of hydroxyapatite crystals of bone, inhibits osteoclast activity

3

Alendronate (Fosamax)
(Uses)

Treatment and prevention of osteoporosis in postmenopausal women, treatment of osteoporosis in men, Paget's disease, treatment of corticosteroid-induced osteoporosis in postmenopausal women in receiving estrogen and in men who are on continuing corticosteroid treatment with low bone mass

4

Alendronate (Fosamax)
(Contraindications)

Hypersensitivity to bisphosphonates, delayed esophageal emptying, inability to sit or stand for 30 min, hypocalcemia

5

Alendronate (Fosamax)
(Side Effects)

CNS: headache
CV: ATRIAL FIBRILLATION
GI: abdominal pain, constipation, nausea, vomiting, esophageal, ulceration, acid reflux, dyspepsia, ESOPHAGEAL PERFORATION, diarrhea, ESOPHAGEAL CANCER
META: hypophosphatemia, hypocalcemia
MS: bone pain, osteonecrosis of the jaw, bone fractures
SYST: ANGIOEDEMA, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS

6

Alendronate (Fosamax)
(Nursing Considerations)

ASSESS:
-Serious reactions: angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, atrial fibrillation
-Hormonal status if a woman, before treatment
-FOR OSTEOPOROSIS: bone density test before and during treatment
-FOR PAGET'S DISEASE: increased skull size, bone pain, headache; decreased vision, hearing
-Electrolytes; BUN/creatinine; calcium, phosphorous, magnesium, potassium
-FOR HYPERCALCEMIA: paresthesia, twitching, laryngospasm; Chvostek's, Trousseau's signs
-Alk phos levels, baseline and periodically, 2 x upper limit of normal is indicative of Paget's disease
-Dental status: regular dental exams should be performed; dental extractions (cover with antiinfectives before procedure)

7

Dinoprostone (Cervidil)
(Functional Classification)

Oxytocic, abortifacient

8

Dinoprostone (Cervidil)
(Chemical Classification)

Prostaglandin E2

9

Dinoprostone (Cervidil)
(Mechanism of Action)

Stimulates uterine contractions, causing abortion; acts within 30hr for complete abortion

10

Dinoprostone (Cervidil)
(Uses)

Abortion during 2nd trimester, benign hydatidiform mole, expulsion of uterine contents in fetal deaths to 28 wk, missed abortion, to efface and dilate the cervix in pregnancy at term

11

Dinoprostone (Cervidil)
(Contraindications)

Hypersensitivity, C-section, surgery

12

Dinoprostone (Cervidil)
(Side Effects)

CNS: Headache, dizziness, chills, fever, flushing
CV: hypotension, DYSRHYTHMIAS, DIC
EENT: blurred vision
SYST: ANAPHYLACTOID SYNDROME OF PREGNANCY
FETAL: bradycardia (i.e., deceleration)
GI: Nausea, Vomiting, Diarrhea
GU: vaginitis, vaginal pain, vulvitis, vaginismus
INTEG: rash, skin color changes
MS: Leg Cramps, Joint Swelling, weakness
GEL: uterine contractile abnormality, GI side effects, back pain, fever
INSERT: uterine hyperstimullation, fever, nausea, vomiting, diarrhea, abdominal pain
SUPPOSITORY: UTERINE RUPTURE, ANAPHYLAXIS

13

Dinoprostone (Cervidil)
(Nursing Considerations)

ASSESS:
-CERVICAL RIPENING: dilation, effacement of cervix and uterine contraction, fetal heart tones, check for contractions over 1 min
-For fever that occurs 1/2hr after suppository insertion (abortion)
-Respiratory rate, rhythm, depth; notify prescriber of abnormalities, pulse, BP, temp
-VAGINAL DISCHARGE: check for itching, irritation; indicates vaginal infection

14

Methylergonovine (Methergine)
(Functional Classification)

Oxytocic

15

Methylergonovine (Methergine)
(Chemical Classification)

Ergot alkaloid

16

Methylergonovine (Methergine)
(Mechanism of Action)

Stimulates uterine, vascular, and smooth muscle, thereby causing contractions; decreases bleeding; arterial vasoconstriction

17

Methylergonovine (Methergine)
(Uses)

Treatment of hemorrhage postpartum or postabortion, uterine contractions

18

Methylergonovine (Methergine)
(Contraindications)

Pregnancy, hypertension, PID, respiratory/cardiac disease, peripheral vascular disease, angina, arteriosclerosis, CAD, dysfunctional uterine bleeding, eclampsia, MI, neonates, Raynaud's disease, sepsis, stroke, Buerger's disease, thrombophlebitis, hypersensitivity to ergot preparations

19

Methylergonovine (Methergine)
(Side Effects)

CNS: Headaches, Dizziness, SEIZURES
CV: HYPOTENSION, chest pain, palpitation, HYPERTENSION, DYSRHYTHMIAS, CVA (IV)
EENT: tinnitus
GI: Nausea, Vomiting
GU: cramping
INTEG: sweating, rash, allergic reactions
RESP: dyspnea

20

Methylergonovine (Methergine)
(Nursing Considerations)

ASSESS:
-BP, pulse, character and amount of vaginal bleeding; watch for indications of hemorrhage
-Uterine relaxation; observe for severe cramping
-ERGOT TOXICITY: tinnitus, hypertension, palpitations, chest pain, nausea, vomiting, weakness; cold, numb extremities

21

Oxytocin (Pitocin)
(Functional Classification)

Hormone

22

Oxytocin (Pitocin)
(Chemical Classification)

Oxytocic, uterine-active agent

23

Oxytocin (Pitocin)
(Mechanism of Action)

Acts directly on myofibrils, thereby producing uterine contraction; stimulates milk ejection by the breast; vasoactive antidiuretic effect

24

Oxytocin (Pitocin)
(Uses)

Stimulation, induction of labor, missed or incomplete abortion; postpartum bleeding

25

Oxytocin (Pitocin)
(Contraindications)

Hypersensitivity, serum toxemia, cephalopelvic disproportion, fetal distress, hypertonic uterus, prolapsed umbilical cord, active genital herpes

26

Oxytocin (Pitocin)
(Side Effects)

CNS: SEIZURES, TETANIC CONTRACTIONS
CV: hypo/hypertension, dysrhythmias, increased pulse, bradycardia, tachycardia, PVC
FETUS: dysrhythmias, jaundice, hypoxia, INTRACRANIAL HEMORRHAGE
GI: anorexia, nausea, vomiting, constipation
GU: ABRUPTIO PLACENTAE, DECREASED UTERINE BLOOD FLOW
HEMA: increased hyperbilirubinemia
INTEG: rash
RESP: ASPHYXIA
SYST: water intoxication of mother

27

Oxytocin (Pitocin)
(Nursing Considerations)

ASSESS:
-I&O ratio
-BP, pulse; watch for changes that may indicate hemorrhage
-Respiratory rate, rhythm, depth; notify prescriber of abnormalities
-Length, intensity, duration of contraction; notify prescriber of contractions lasting >1 min or absence of contractions; turn patient on her side; discontinue oxytocin
-FHTs, fetal distress; watch for acceleration, deceleration; notify prescriber if problems occur; fetal presentation, pelvic dimensions; turn patient on left side if FHT change in rate, give O2
-WATER INTOXICATION; confusion, anuria, drowsiness, headache